Sodium channel blocker tests allow a clear distinction of electrophysiological characteristics and prognosis in patients with a type 2 or 3 Brugada electrocardiogram pattern

Heart Rhythm. 2008 Nov;5(11):1561-4. doi: 10.1016/j.hrthm.2008.08.029. Epub 2008 Aug 31.

Abstract

Background: Patients with a type 2 or 3 Brugada syndrome (BS) pattern and a negative sodium channel blocker challenge (SCBC) are not considered as affected. Their arrhythmic prognosis is generally considered good, but it has never been specifically evaluated.

Objective: The purpose of this study was to evaluate the arrhythmic prognosis in patients with a type 2 or 3 electrocardiogram (ECG) not converted to type 1 ECG during an SCBC.

Methods: Clinical data, 12-lead ECG, results of the SCBC and electrophysiological study (EPS), and follow-up were collected.

Results: Among the 500 patients who underwent an SCBC in our institution, 158 displayed a type 2 or 3 ECG. After the SCBC, 93 (59%) had a type 1 ECG (positive group [PG]), whereas 65 (41%) remained negative (negative group [NG]). An EPS was performed in 31 (33%) PG patients and 15 (23%) NG patients. Ventricular fibrillation was induced in 21 PG patients (67%), whereas no patient in the NG was inducible (P <.001). During a follow-up of 37 +/- 17 months, no sudden death occurred. Three syncopes were observed in the NG versus one syncope, two ventricular tachycardias, and one appropriate shock in the PG.

Conclusion: This study demonstrates that the presence or absence of coved type ST-segment elevation during the SCBC denotes a profound electrophysiological difference as demonstrated by the absence of inducibility during EPS in the NG that may be responsible for the good prognosis of patients with a type 2 or 3 ECG pattern not converted to type 1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Brugada Syndrome / complications*
  • Brugada Syndrome / physiopathology*
  • Cardiac Electrophysiology
  • Electrocardiography
  • Female
  • Heart Conduction System / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Sodium Channel Blockers / pharmacology*
  • Tachycardia, Ventricular / etiology*

Substances

  • Sodium Channel Blockers